COMP <GO>
PEN vs MRK // RETURN ON INVESTED CAPITAL (ROIC)
Penumbra Inc. (NYSE) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: PEN 3
— MRK 11
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: MRK
LAST: $318.95 (-0.94%) • MKT CAP: $12.68B
roic
10.60%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
roic
20.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PEN VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PEN | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 67.10% | 74.80% | -7.70 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 10.60% | 20.70% | -10.10 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 52.0x | 15.3x | +36.70 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 1.38% | 3.42% | -2.04 | MRK | /fcf-yield <GO> |
| Operating Margin | 13.50% | 34.30% | -20.80 | MRK | /operating-margins <GO> |
| Net Profit Margin | 12.70% | 28.10% | -15.40 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 17.50% | 1.30% | +16.20 | PEN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 21.05 | 5.19 | +15.86 | PEN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | PEN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.60% | 6.60% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.7 | 56.9 | -12.13 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.91 | 0.92 | -0.01 | MRK | /macro-sensitivity <GO> |
| Forward P/E Multiple | 60.0x | 18.4x | +41.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $12.68B | $361.02B | -$348.34B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PEN REV | MRK REV | PEN GROSS % | MRK GROSS % | PEN FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.40B | $65.01B | 67.1% | 74.8% | $174.9M | $12.36B |
| FY 2024 | $1.19B | $64.17B | 63.2% | 76.3% | $147.3M | $18.10B |
| FY 2023 | $1.06B | $60.12B | 44.0% | 44.0% | $49.7M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PEN // BETA 0.91
MRK // BETA 0.92